|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0086589,
umls-concept:C0205171,
umls-concept:C0456387,
umls-concept:C0596545,
umls-concept:C0600558,
umls-concept:C0681842,
umls-concept:C0868928,
umls-concept:C0871261,
umls-concept:C1441616,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-3-10
|
|
pubmed:abstractText |
Complete pathologic response to neoadjuvant chemotherapy (NACT) is predominantly seen in "ERBB2" and "basal-like" tumors using expression profiling. We hypothesize that a similar response could be predicted using semiquantitative immunohistochemistry for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1431-9
|
|
pubmed:dateRevised |
2011-5-19
|
|
pubmed:meshHeading |
pubmed-meshheading:20131351-Adult,
pubmed-meshheading:20131351-Aged,
pubmed-meshheading:20131351-Aged, 80 and over,
pubmed-meshheading:20131351-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20131351-Breast Neoplasms,
pubmed-meshheading:20131351-Disease-Free Survival,
pubmed-meshheading:20131351-Female,
pubmed-meshheading:20131351-Humans,
pubmed-meshheading:20131351-Immunohistochemistry,
pubmed-meshheading:20131351-Middle Aged,
pubmed-meshheading:20131351-Neoadjuvant Therapy,
pubmed-meshheading:20131351-Neoplasm Staging,
pubmed-meshheading:20131351-Prognosis,
pubmed-meshheading:20131351-Receptor, erbB-2,
pubmed-meshheading:20131351-Receptors, Estrogen,
pubmed-meshheading:20131351-Receptors, Progesterone,
pubmed-meshheading:20131351-Treatment Outcome,
pubmed-meshheading:20131351-Tumor Markers, Biological
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
|
|
pubmed:affiliation |
Department of Pathology, Magee-Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA. rbhargava@mail.magee.edu
|
|
pubmed:publicationType |
Journal Article
|
